RxDoctor Payments DataLook up a doctor →

David Greer, MD

Neurology · Huntsville, ALNPI 1013064815

Payments from drug & device makers

$66,785in general payments, 2019–2025

Across 2,488 payments — averaging $26.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acorda Therapeutics, Inc$13K
  • Livanova USA, Inc.$7K
  • AbbVie$4K
  • MDD US Operations, LLC$4K
  • UCB, Inc.$4K
  • Novartis$2K
  • plus $33K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Acorda Therapeutics, Inc61$12,812
Livanova USA, Inc.18$6,764
AbbVie(2 entities)291$3,934
MDD US Operations, LLC51$3,735
UCB, Inc.244$3,571
Novartis152$2,496
Biogen158$2,280
CSL Behring78$2,249
Pfizer103$1,730
Boston Scientific9$1,499
Neurocrine Biosciences, Inc.70$1,331
SK Life Science, Inc.57$1,245
Amgen(2 entities)59$1,238
Teva Pharmaceuticals USA, Inc.69$1,151
AstraZeneca50$1,144
EMD Serono, Inc.67$1,129
Lilly USA, LLC63$1,019
Acadia Pharmaceuticals Inc62$1,016
Argenx US, Inc.35$902
Harmony Biosciences LLC29$735
Supernus Pharmaceuticals, Inc.54$731
Avanir Pharmaceuticals, Inc.36$707
Bristol Myers Squibb31$695
Jazz Pharmaceuticals Inc.33$649
Sunovion Pharmaceuticals Inc.42$611
Otsuka America Pharmaceutical, Inc.28$601
Adamas Pharmaceuticals, Inc.32$600
Lundbeck LLC33$567
Grifols USA, LLC29$566
Catalyst Pharmaceuticals, Inc.26$556
Eisai Inc.38$525
Greenwich Biosciences, Inc.15$508
Kyowa Kirin, Inc.28$495
Medtronic4$488
Johnson & Johnson(2 entities)26$487
Sanofi22$443
Merz Pharmaceuticals, LLC19$417
Ipsen Biopharmaceuticals, Inc15$326
Neurelis, Inc.15$315
Amneal Pharmaceuticals LLC22$315
Genentech USA, Inc.18$315
Arbor Pharmaceuticals, Inc.13$290
Biohaven Pharmaceuticals, Inc.12$288
Impel Pharmaceuticals Inc.15$282
Biohaven Pharmaceutical Holding Company Ltd.12$267
Sumitomo Pharma America, Inc.11$224
Cycle Pharmaceuticals Inc10$218
Axsome Therapeutics, Inc.8$165
Upsher-smith Laboratories LLC8$149
C. R. Bard, Inc. & Subsidiaries2$140
Merck8$138
Takeda Pharmaceuticals U.S.A., Inc.7$136
Scilex Pharmaceuticals Inc.7$133
Impel Pharmaceuticals LLC6$131
TG Therapeutics, Inc.7$129
Currax Pharmaceuticals LLC7$101
Akcea Therapeutics, Inc.5$101
Banner Life Sciences, LLC5$97
Merz North America, Inc.6$90
Aucta Pharmaceuticals, Inc.3$84

How this compares

$66,785 in reported general payments places this provider in the 80th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama →

Medicare billing

Part B allowed, 2024
$527,921
Medicare patients
972
Services billed
31,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Huntsville

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →